# Sitagliptin in Recurrent/Progressive Grade 4 Glioma

> **NCT07541781** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Kailin Yang, MD, PhD** · enrollment: 45 (estimated)

## Conditions studied

- Glioma
- Glioblastoma
- Recurrent Glioma
- Recurrent Glioblastoma
- Grade 4 Malignant Glioma of Brain (Disorder)

## Interventions

- **DRUG:** Sitagliptin
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT07541781
- **Lead sponsor:** Kailin Yang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2029-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541781, "Sitagliptin in Recurrent/Progressive Grade 4 Glioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07541781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*